A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Epistemonikos ID: f2f8ad6ca4b723d3a26fb853b3b1c5131fec9fb1
First added on: May 07, 2024